A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Giuseppe Procopio; Mélanie Claps; Chiara Pircher; Luca Porcu; Pierangela Sepe; Valentina Guadalupi; Ugo De Giorgi; Davide Bimbatti; Franco Nolè; Francesco Carrozza; Sebastiano Buti; Roberto Iacovelli; Chiara Ciccarese; Cristina Masini; Cinzia Baldessari; Laura Doni; Antonio Cusmai; Angela Gernone; Sarah Scagliarini; Sandro Pignata; Filippo de Braud; Elena Verzoni

doi:10.1177/03008916221138881

Abstract

This is the authors' abstract. We don't add key points for this paper.

NCT03463681 - A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma (BREAKPOINT) - https://clinicaltrials.gov/ct2/show/NCT03463681.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Procopio et al. (2022) studied this question.

synapsesocial.com/papers/69d7c6373b601d7be3ae2db1 https://doi.org/10.1177/03008916221138881

View Full Paper

Ask AI

Bookmark

Share

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Abstract

Ask about this paper

Discussion

Cite This Study

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading